Xeris Biopharma Holdings (NASDAQ: XERS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.250 | -0.250 | 0.0000 | ||||
REV | 23.590M | 21.910M | -1.680M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Xeris Biopharma Holdings (NASDAQ: XERS) through any online brokerage.
There are no as such competitors for Xeris Biopharma Holdings.
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by Craig-Hallum on Thursday, April 28, 2022. The analyst firm set a price target for 6.50 expecting XERS to rise to within 12 months (a possible 308.81% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Xeris Biopharma Holdings (NASDAQ: XERS) is $1.59 last updated July 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Xeris Biopharma Holdings.
Xeris Biopharma Holdings’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Xeris Biopharma Holdings.
Xeris Biopharma Holdings is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.